- Home
- ACRV vs DXR Comparison
ACRV vs DXR Comparison
Compare ACRV & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRV | DXR |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 66.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | DXR |
|---|---|---|
| Price | $2.39 | $13.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $14.67 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.3M | 5.1K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $805.34 | N/A |
| P/E Ratio | ★ N/A | $36.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.05 | $6.55 |
| 52 Week High | $8.00 | $14.15 |
Technical Indicators
Market Signals| Indicator | ACRV | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 51.62 |
| Support Level | $2.22 | $12.91 |
| Resistance Level | $2.39 | $13.53 |
| Average True Range (ATR) | 0.18 | 0.47 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 86.15 | 60.08 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.